Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $18.3 million.

  • Theravance Biopharma's Receivables - Other rose 844.17% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 844.17%. This contributed to the annual value of $18.4 million for FY2024, which is 552.82% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Receivables - Other is $18.3 million, which was up 844.17% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Receivables - Other ranged from a high of $43.8 million in Q3 2021 and a low of $12.3 million during Q1 2023
  • Over the past 5 years, Theravance Biopharma's median Receivables - Other value was $16.8 million (recorded in 2024), while the average stood at $20.5 million.
  • The largest annual percentage gain for Theravance Biopharma's Receivables - Other in the last 5 years was 6117.11% (2021), contrasted with its biggest fall of 7385.64% (2021).
  • Over the past 5 years, Theravance Biopharma's Receivables - Other (Quarter) stood at $14.1 million in 2021, then increased by 19.34% to $16.8 million in 2022, then increased by 4.1% to $17.5 million in 2023, then increased by 5.53% to $18.4 million in 2024, then fell by 0.94% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $21.9 million for Q2 2025, and $15.4 million during Q1 2025.